A comparison of depot and oral atypical antipsychotics in terms of metabolic syndrome markers

Demet Sağlam Aykut and Evrim Özkorumak Karagüzel

Department of Psychiatry, Faculty of Medicine, Karadeniz Technical University, Trabzon, Turkey

ABSTRACT

OBJECTIVES: The duration of life of patients with schizophrenia is shorter than that of the general population for various reasons. Especially cardiovascular diseases are one of the most important causes of death in patients with schizophrenia. Our aim in this study is comparison of second-generation depot antipsychotics and second-generation oral antipsychotics used in the treatment of patients with schizophrenia in terms of metabolic syndrome criteria.

METHODS: We included 39 patients treated with second-generation depot antipsychotics and 124 patients treated with second-generation oral antipsychotics, who were diagnosed with schizophrenia. Positive and Negative Syndrome Scale was applied to all the patients and blood pressure, weight, height, body mass index, waist circumference, fasting blood glucose, triglyceride level, and high-density lipoprotein (HDL) levels were recorded.

RESULTS: In terms of metabolic syndrome criteria, the waist circumference and triglyceride levels of the patients treated with the second-generation depot antipsychotics were lower than those of the patients treated with second-generation oral antipsychotics, and the HDL levels were statistically significantly higher.

CONCLUSION: In this study, second-generation depot antipsychotics used in the treatment of schizophrenia patients were found to be associated with more positive results in terms of metabolic syndrome criteria than oral antipsychotic drug forms.

Introduction

The life span of patients with schizophrenia is lower than that of society in general for various reasons, such as the prevalence of accidents, cardiovascular disease (CVD), and contagious diseases among these patients [1,2]. CVDs are one of the principal causes of death of patients with schizophrenia. These patients have a 2- to 3-fold greater risk of CVD than healthy controls [2], and CVDs are responsible for 45% of the increased mortality seen in patients with schizophrenia [3].

Patients with schizophrenia are known to be at risk in terms of CVDs and cerebrovascular events due to various factors, including poor diet, tobacco use, weight gain, and low levels of physical exercise [4–6]. Higher fasting blood sugar and insulin resistance have been reported in patients with schizophrenia who have never been exposed to antipsychotic therapy [7]. In addition, various drugs, particularly antipsychotics, have been identified in recent years as having adverse effects in terms of CVD development [8]. Studies have reported that, in addition to increased risk factors in patients with schizophrenia, antipsychotic therapy itself increases the risk of metabolic irregularities, weight gain, and obesity [9]. Several wide-ranging reviews have revealed that atypical antipsychotics significantly increase the risk of CVDs, such as diabetes, compared to typical antipsychotics [10]. Some studies have reported a higher incidence of diabetes and hypertension in patients with schizophrenia compared to healthy controls [11]. The increased prevalence of CVD, diabetes, and hypertension and greater mortality may partly be attributed to metabolic syndrome [1]. The metabolic syndrome including visceral adiposity, insulin resistance, increased blood pressure, elevated triglyceride levels, and low high-density lipoprotein (HDL) cholesterol levels is an important risk factor for CVD [12]. The prevalence of metabolic syndrome is reported to be 2–4 times higher in patients with schizophrenia than in healthy individuals [13,14].

Due to high rate of adherence with long-acting antipsychotics has better protection than oral antipsychotics [15], but they have been associated with further adverse events, including metabolic disturbances and cardiovascular events [16,17]. The purpose of this study was to compare second-generation depot antipsychotics and oral antipsychotics used in the treatment of patients with schizophrenia in terms of metabolic syndrome criteria.
Materials and methods

Sampling

Patients presenting to the psychiatry clinic of a regional Mental and Neurological Diseases Hospital between January and July, 2014, diagnosed with schizophrenia based on Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I), under the observation with second-generation depot antipsychotics or second-generation oral antipsychotics for the previous 9 months based on information from psychiatrists and patient record checks, and identified as not being in the active disease period based on clinical decisions and a Positive and Negative Syndrome Scale (PANSS) score <70, were cross-sectionally included in the study. Thirty-nine of the patients enrolled were being treated with depot antipsychotics and 124 with oral antipsychotics. The patients enrolled were not using any psychotropic medication other than antipsychotics. Patients’ treatments were initiated and maintained by other physicians, and patients were evaluated in a cross-sectional manner by the same author in terms of study data production. Overnight fasting blood tests were requested by monitoring physicians for routine control purposes. They were later evaluated by the authors for the purpose of this study.

Patients included in the study were informed about the research. Once written informed consent had been obtained, sociodemographic characteristics were recorded. All patients were consecutively administered the PANSS in order to determine the severity of symptoms. Blood pressure values, weight, height, body mass index (BMI) and waist circumference, and biochemical tests including triglyceride and HDL levels and fasting blood glucose requested by patients’ physicians for routine control purposes were recorded.

Subjects with additional psychiatric diagnoses in addition to schizophrenia based on DSM-IV at the application of SCID-I, with a previous diagnosis of dementia, with a history of physical disease affecting the central nervous system, with a history of head trauma resulting in loss of consciousness, with mental retardation or from whom informed consent could not be obtained were excluded from the study. Patients using psychotropic drugs other than antipsychotics were not included in the study.

The study commenced following official permission from the Province of Trabzon Public Hospitals’ Union General Secretariat Kanuni Training and Research Hospital Clinical Research Ethical Committee and the hospital management.

Evaluation tools

Sociodemographic data form

This form was designed by the authors of the study in order to evaluate patients’ sociodemographic characteristics (such as age, sex, marital status, and employment status) and clinical characteristics (such as age at onset of disease, total duration of disease, and total number of hospitalizations).

Structured clinical interview for DSM-IV axis I disorders (SCID-I)

SCID-I was developed in 1987 for the diagnosis of DSM-III-R axis I disorders using a structured clinical evaluation tool [18]. It was subsequently updated for DSM-IV.

Positive and negative syndrome scale (PANSS)

The PANSS is a semi-structured interview scale was developed by Kay et al. [19] consisting of 30 items and involving a 7-point evaluation of symptom severity. Seven of the 30 psychiatric parameters belong to the positive symptoms subscale, 7 to the negative symptoms subscale, and the remaining 16 to the general psychopathology subscale. The reliability and validity of the Turkish-language version were established by Kostakoğlu et al. [20].

Statistical analysis

Normal distribution of variables was examined using the Kolmogorov–Smirnov test. Descriptive data were expressed as mean and standard deviation for normally distributed variables and median and minimum – maximum values for non-normally distributed variables. The chi-square test was used to compare qualitative data, Student’s t-test for normally distributed parameters and the Mann–Whitney U-test for non-normally distributed parameters. p-Values less than 0.05 were regarded as statistically significant.

Results

Sixty-seven (41.1%) of the 163 patients included in the study were female and 96 (58.9%) were male. Thirteen (33.3%) of the patients treated with second-generation depot antipsychotics were women and 26 (66.7%) were men. Fifty-four (43.5%) of the patients treated with second-generation oral antipsychotics were women and 70 (56.5%) were men. The mean age of the patients using depot antipsychotics was 37.41 ± 9.11, and the mean age of those using oral antipsychotics was 37.57 ± 10.64. There was no statistically significant difference between the second-generation depot and oral antipsychotic groups in terms of sex or age. Eighty-six (52.8%) of the subjects were single, and 75 (46.0%) had income generating occupations. A statistically significant difference was determined between the two groups in terms of marital status (p = 0.027), but none in terms of other sociodemographic characteristics (p > 0.05). In terms of clinical characteristics, no difference was determined between the patients using...
depot or oral antipsychotic drugs in terms of total duration of disease or total length of last treatment ($p > 0.05$) (Table 1).

The 39 patients receiving the second-generation depot antipsychotics were not using any additional antipsychotic therapy. The second-generation antipsychotics used and the dose ranges were: risperidone consta 25, 37.5, and 50 mg once every 15 days, paliperidone palmitate 75, 100, and 150 mg once monthly. One hundred and nine of the 124 patients treated with the second-generation oral antipsychotics were receiving a single medication and 15 were receiving two. The dosage ranges of the second-generation antipsychotics used were: quetiapine 600–1100 mg/day, olanzapine 6–9 mg/day, aripiprazole 15–30 mg/day, risperidone 4–8 mg/day, amisulpride 600–1200 mg/day, and clozapine 200–600 mg/day.

When the patient groups using depot and oral antipsychotic groups were compared in terms of PANSS scores, a significant difference was observed in terms of PANSS P scores ($p = 0.028$), but none in respect of PANNS N or PANNS G ($p = 0.068, p = 0.664$). No significant variation was determined between the two groups in terms of metabolic values such as systolic blood pressure, diastolic blood pressure, weight, BMI, or fasting blood glucose ($p > 0.05$), while triglyceride levels were significantly lower in the depot antipsychotic group than the oral antipsychotic group ($p = 0.020$). HDL levels were significantly higher in the patients using depot antipsychotics ($p < 0.001$), while triglyceride levels were significantly lower ($p = 0.004$) (Table 2).

When patients using two antipsychotic agents ($n = 15$) were excluded and patients using a single antipsychotic ($n = 109$) were compared with those using depot antipsychotics ($n = 36$), variations in the subjects using depot antipsychotics compared to those using oral antipsychotics in terms of waist circumference, low triglyceride levels and high HDL levels were continue to be significant ($p = 0.025, p = 0.001, p = 0.041$).

**Discussion**

The five principal components of metabolic syndrome are abdominal obesity, hypertension, increased fasting blood glucose level, hypertriglyceridemia, and a severe reduction in HDL level. Table 1 shows the socio-demographic and clinical characteristics of study groups. Table 2 shows the comparison between depot and oral antipsychotics in terms of PANSS, blood pressure, weight, BMI, waist circumference, HDL, TG, fasting blood glucose values of study groups.

---

**Table 1.** Socio-demographic and clinical characteristics of study groups.

|                | Depot AP (n = 39) | Oral AP (n = 124) | p   |
|----------------|------------------|------------------|-----|
| Age [Mean ± SD] | 37.41 ± 9.11     | 37.57 ± 10.64    | 0.932** |
| Gender [n (%)]  |                  |                  |     |
| Women           | 13 (33.3)        | 54 (43.5)        | 0.345*  |
| Men             | 26 (66.7)        | 70 (56.5)        |     |
| Marital status [n (%)] |     |                  |     |
| Single          | 24 (61.5)        | 62 (50.0)        | 0.027*  |
| Married         | 8 (20.6)         | 52 (41.9)        |     |
| Widow           | 7 (17.9)         | 10 (8.1)         |     |
| Duration of education (years) [Mean ± SD] | 9.36 ± 2.53 | 9.36 ± 3.58 | 0.995** |
| Employment status [n (%)] |     |                  |     |
| Positive        | 19 (48.7)        | 56 (45.2)        | 0.838*  |
| Negative        | 20 (51.3)        | 68 (54.8)        |     |
| Smoking status [n (%)] |     |                  |     |
| Positive        | 18 (46.2)        | 54 (43.5)        | 0.791*  |
| Negative        | 21 (53.8)        | 70 (56.5)        |     |
| Substance, alcohol status [n (%)] |     |                  |     |
| Positive        | 1 (2.6)          | 4 (3.2)          | 1.000*  |
| Negative        | 38 (97.4)        | 120 (56.9)       |     |
| Total usage time of the last treatment (months) [Median (min – max)] | 12 (6 – 96) | 12 (6 – 96) | 0.484*** |
| Total duration of disease (years) [Mean ± SD] | 13.13 ± 8.49 | 12.05 ± 8.63 | 0.495** |

Notes: Mean ± SD: mean ± standard deviation. *Ki-kare testi, **Student t testi, ***Mann–Whitney U testi.

**Table 2.** Comparison of PANNS, blood pressure, weight, BMI, waist circumference, HDL, TG, fasting blood glucose values of study groups.

|                | Depot AP (n = 39) | Oral AP (n = 124) | p   |
|----------------|------------------|------------------|-----|
| PANSS P [Median (min – max)] | 8 (7 – 20) | 7.5 (7 – 20) | 0.028*  |
| PANSS N [Median (min – max)] | 7 (7 – 23) | 7 (7 – 27) | 0.068*  |
| PANSS G [Median (min – max)] | 16 (16 – 32) | 17 (15 – 38) | 0.664*  |
| Systolic blood pressure [Mean ± SD] | 120 (100 – 140) | 120 (90 – 170) | 0.435*  |
| Diastolic blood pressure [Mean ± SD] | 80 (60 – 90) | 80 (60 – 90) | 0.220*  |
| Weight [Mean ± SD] | 82.87 ± 12.05 | 83.94 ± 17.57 | 0.668** |
| BMI [Mean ± SD] | 28.53 ± 4.66 | 30.01 ± 6.34 | 0.179** |
| Waist circumference [Mean ± SD] | 90.23 ± 11.99 | 96.65 ± 15.61 | 0.020** |
| HDL [Mean ± SD] | 50.33 ± 12.08 | 43.09 ± 10.35 | <0.001** |
| TG [Mean ± SD] | 131.00 ± 57.81 | 168.32 ± 90.51 | 0.003** |
| Fasting blood glucose [Mean ± SD] | 91.79 ± 19.16 | 90.00 ± 14.16 | 0.531** |

Notes: AP: antipsychotic; BMI: body mass index; HDL: high-density lipoprotein; mean ± SD: mean ± standard deviation; PANSS: Positive and Negative Syndrome Scale; TG: triglyceride. *Mann–Whitney U testi, **Student t testi.
D. SAGLAM AYKUT AND E. OZKORUMAK KARAGUZEL

288

Disclosure statement

No potential conflict of interest was reported by the authors.
References

[1] Lee JS, Kwon JS, Kim D, et al. Prevalence of metabolic syndrome in patients with schizophrenia in Korea: a multicenter nationwide cross-sectional study. Psychiatry Invest. 2017;14(1):44–50.

[2] Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry. 2000;177:212–217.

[3] Osby U, Correia N, Brandt L, et al. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res. 2000;45:21–28.

[4] Dixon L, Weiden P, Delahanty J, et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull. 2000;26:903–912.

[5] Ganesh S, GaAshok AH, Kumar CN, et al. Prevalence and determinants of metabolic syndrome in patients with schizophrenia: a systematic review and meta-analysis of Indian studies. Asian J Psychiatr. 2016;22:86–92.

[6] Verma A, Bajaj S, Verma S, et al. Study of the association of metabolic syndrome with schizophrenia in north eastern part of India. Int J Med Sci Public Health. 2013;2:583.

[7] Ryan MCM, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry. 2003;160:284–289.

[8] De Hert M, Detraux J, van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011;8:114–126.

[9] Meyer JM, Davis VG, Goff DC, et al. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE schizophrenia trial: prospective data from phase I. Schizophr Res. 2008;101:273–286.

[10] De Hert M, Schreurs V, Vancampfort D, et al. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry. 2009;8:15–22.

[11] Bresce LC, Majumdar SR, Patten SB, et al. Prevalence of cardiovascular risk factors and disease in people with schizophrenia: a population-based study. Schizophr Res. 2010;117:75–82.

[12] Huang M, Yu L, Fan F, et al. A randomized, 13-week study assessing the efficacy and metabolic effects of paliperidone palmitate injection and olanzapine in first-episode schizophrenia patients. Prog Neuro-Psychopharmacol Biol Psychiatry. 2018;81(2):122–130.

[13] McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophren Res. 2005;80:19–32.

[14] Lee NY, Kim SH, Jung DC, et al. The prevalence of metabolic syndrome in Korean patients with schizophrenia receiving monotherapies with aripiprazole, olanzapine or risperidone. Prog Neuro-Psychopharmacol Biol Psychiatry. 2011;35:1273–1278.

[15] Tihonen J, Haukka J, Taylor M, et al. Nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011;168:603–609.

[16] Lang K, Meyers JL, Korn JR, et al. Medication adherence and hospitalization among patients with schizophrenia treated with antipsychotics. Psychiatr Serv. 2010;61:1239–1247.

[17] Rosso G, Pessina E, Martini A, et al. Paliperidone palmitate and metabolic syndrome in patients With schizophrenia: a 12-month observational prospective cohort study. J Clin Psychopharmacol. 2016;36 (3):206–212.

[18] Spitzer RL, Williams JBW, Gibbon M. Structured clinical interview for DSM-III-R axis I disorders (SCID-I). Washington (DC): American Psychiatric Press Inc; 1987.

[19] Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276.

[20] Kostakoğlu AE, Batur S, Tiryaki A. Pozitif ve negatif sendrom ölçeginin (PANSS) Türkçe uyarlamasının geçerlilik ve güvenilirliği. Türk Psikoloji Dergisi. 1999;14:23–32.

[21] Rummel-Kluge C, Komossa K, Schwarz S, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2010;123:225–233.

[22] Hu S, Yao M, Peterson BS, et al. A randomized, 12-week study of the effects of extended-release paliperidone (paliperidone ER) and olanzapine on metabolic profile, weight, insulin resistance, and β-cell function in schizophrenic patients. Psychopharmacology (Berl.). 2013;230(1):3–13.

[23] Bergman RN, Adjer M. Atypical antipsychotics and glucose homeostasis. J Clin Psychiatr. 2005;66:504–514.

[24] Citrome L. Evaluation of obesity. Who are the obese? Postgrad Med. 2003;114:19–38.

[25] Wang Y, Rimm EB, Stampfer MJ, et al. Comparison of abdominal adiposity and overall obesity in predicting risk of type 2 diabetes among men. Am J Clin Nutr. 2005;81:555–563.

[26] Kaushal J, Bhutani G, Gupta R. Comparison of fasting blood sugar and serum lipid profile changes after treatment with atypical antipsychotics olanzapine and risperidone. Singapore Med J. 2012;53(7):488–492.

[27] Misra A, Misra R, Wijesuriya M, et al. The metabolic syndrome in South Asians: continuing escalation & possible solutions. Indian J Med Res. 2007;125:345–354.

[28] Avramoglu RK, Qiu W, Adeli K. Mechanisms of metabolic dyslipidemia in insulin resistant states: deregulation of hepatic and intestinal lipoprotein secretion. Front Biosci. 2003;8:d464–d476.

[29] De Hert M, Schreurs V, Sweers K, et al. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr Res. 2008;101:295–303.

[30] Birkenaes AB, Birkeland KI, Engh JA, et al. Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions. J Clin Psychopharmacol. 2008;28:132–137.

[31] Kim JK, Fillmore JI, Chen Y, et al. Tissue-specific over expression of lipoprotein lipase causes tissue resistance. Proc Natl Acad Sci USA. 2001;98:7522–7527.

[32] Meyer JL, Stahl SM. The metabolic syndrome and schizophrenia. Acta Psychiatr Scand. 2009;119:4–14.

[33] Smith RC, Lindenmayer JP, Bank N, et al. Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenic patients. Int J Neuropsychopharmacol. 1999;2:183–194.

[34] Lindenmayer JP, Czobor P, Volavka J, et al. Changes in glucose and cholesterol levels in patient with
schizophrenia treated with typical and atypical antipsychotics. Am J Psychiatry. 2003;160:290–296.

[35] Sikich L, Hamer RM, Bashford RA, et al. A pilot study of risperidone, olanzapine and haloperidol in psychotic youth: a double-blind, randomized, 8-week trial. Neuropsychopharmacology. 2004;29:133–145.

[36] Sikich L, Frazier JA, McClellan J, et al. Double-blind comparison of first and second-generation antipsychotics in early-onset schizophrenia and schizoaffective disorder: findings from the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study. Am J Psychiatry. 2008;165:1420–1431.

[37] Citrome L, Jaffe A, Levine J, et al. Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Psychiatr Serv. 2004;55:1006–1013.